Duke Energy, Watson Pharma: Overlooked M&A Stocks
NEW YORK (TheStreet) -- After a flurry of deals earlier in the week highlighted by a $4.3 billion acquisition of Ariba(ARBA) by German IT services giant SAP(SAP) and Yahoo!'s(YHOO) $7.1 billion sale of a 20% stake in Chinese ecommerce giant Alibaba, the latter half of the week has yielded few notable deals.
With deal headlines on the backburner, investors may want to take another look at M&A headlines from recent weeks they may have overlooked.
Take Watson Pharmaceuticals'(WAT) acquisition of Swiss generics drug maker Actavis, or Boyd Gaming's(BYD) bet on casino operator Peninsula Gaming. Recent analyst ratings and reactions provide insightful seconds reads on the deals.
On Thursday, Wells Fargo upgraded Watson Pharmaceuticals to outperform from market perform and boosted its projected share price range to between $84 and $90 (previously $75-$79) on higher confidence in the benefits of its $5.6 billion acquisition of Actavis from late April. Watson Pharmaceuticals rose at the end of April when management announced a cheaper than expected acquisition that was projected to wrench out higher than expected cost synergies and earnings gains.
When the deal is completed, Watson Pharmaceuticals expects to tilt 40% of its generic drugs revenue outside of the U.S. Those benefits and synergies are expected to add 30% to Watson's non-GAAP 2013 earnings per share, causing analysts like Credit Suisse's Mike Faerm and Corey Davis of Jefferies to boost their share expectations for Watson Pharmaceuticals, as it takes on larger generics competitors Mylan(MYP) , Sandoz and Teva Pharmaceutical(TEVA) .